
Amber D. Steele
Examiner (ID: 2430, Phone: (571)272-5538 , Office: P/1676 )
| Most Active Art Unit | 1658 |
| Art Unit(s) | 1654, 1639, 1658, 1676 |
| Total Applications | 1302 |
| Issued Applications | 628 |
| Pending Applications | 166 |
| Abandoned Applications | 538 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17890747
[patent_doc_number] => 11453700
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-27
[patent_title] => Peptide having activities of skin whitening and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/625841
[patent_app_country] => US
[patent_app_date] => 2019-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 4
[patent_no_of_words] => 4018
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16625841
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/625841 | Peptide having activities of skin whitening and uses thereof | Oct 9, 2019 | Issued |
Array
(
[id] => 17336014
[patent_doc_number] => 20220002345
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => Bone-Targeting Therapeutic Compositions and Methods of Using Them
[patent_app_type] => utility
[patent_app_number] => 17/283312
[patent_app_country] => US
[patent_app_date] => 2019-10-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3388
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283312
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/283312 | Bone-Targeting Therapeutic Compositions and Methods of Using Them | Oct 7, 2019 | Abandoned |
Array
(
[id] => 19367390
[patent_doc_number] => 12059450
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-13
[patent_title] => Anticancer pharmaceutical composition containing IF1 as active ingredient
[patent_app_type] => utility
[patent_app_number] => 17/281808
[patent_app_country] => US
[patent_app_date] => 2019-10-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 7
[patent_no_of_words] => 6174
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281808
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/281808 | Anticancer pharmaceutical composition containing IF1 as active ingredient | Oct 1, 2019 | Issued |
Array
(
[id] => 17426065
[patent_doc_number] => 20220053773
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOGENIC INFECTIONS IN PLANTS
[patent_app_type] => utility
[patent_app_number] => 17/281884
[patent_app_country] => US
[patent_app_date] => 2019-10-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37290
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281884
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/281884 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOGENIC INFECTIONS IN PLANTS | Sep 30, 2019 | Pending |
Array
(
[id] => 16191109
[patent_doc_number] => 20200231958
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-23
[patent_title] => FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
[patent_app_type] => utility
[patent_app_number] => 16/589851
[patent_app_country] => US
[patent_app_date] => 2019-10-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11967
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16589851
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/589851 | FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION | Sep 30, 2019 | Abandoned |
Array
(
[id] => 20621654
[patent_doc_number] => 12589148
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-31
[patent_title] => Immunity-inducing agent comprising antigen peptide-adjuvant nucleotide conjugate and pharmaceutical composition comprising same
[patent_app_type] => utility
[patent_app_number] => 17/280605
[patent_app_country] => US
[patent_app_date] => 2019-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 7
[patent_no_of_words] => 6896
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 190
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17280605
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/280605 | Immunity-inducing agent comprising antigen peptide-adjuvant nucleotide conjugate and pharmaceutical composition comprising same | Sep 26, 2019 | Issued |
Array
(
[id] => 17198493
[patent_doc_number] => 20210338587
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => INJECTABLE COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/279807
[patent_app_country] => US
[patent_app_date] => 2019-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17932
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279807
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/279807 | INJECTABLE COMPOSITION | Sep 26, 2019 | Abandoned |
Array
(
[id] => 15361495
[patent_doc_number] => 20200016512
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-16
[patent_title] => AFFINITY SEPARATION MATRIX FOR PURIFYING IMMUNOGLOBULIN
[patent_app_type] => utility
[patent_app_number] => 16/586054
[patent_app_country] => US
[patent_app_date] => 2019-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10155
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16586054
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/586054 | AFFINITY SEPARATION MATRIX FOR PURIFYING IMMUNOGLOBULIN | Sep 26, 2019 | Abandoned |
Array
(
[id] => 17398165
[patent_doc_number] => 20220040255
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => CHEMOTHERAPEUTIC REMODELING OF THE GUT MICROBIOME
[patent_app_type] => utility
[patent_app_number] => 17/280660
[patent_app_country] => US
[patent_app_date] => 2019-09-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17089
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17280660
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/280660 | CHEMOTHERAPEUTIC REMODELING OF THE GUT MICROBIOME | Sep 25, 2019 | Abandoned |
Array
(
[id] => 15960569
[patent_doc_number] => 20200164036
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-28
[patent_title] => METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS AND PREDICTION OF CLINICAL SENSITIVITY TO TREATMENT OF BILE ACID-RELATED DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/562150
[patent_app_country] => US
[patent_app_date] => 2019-09-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47968
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16562150
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/562150 | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders | Sep 4, 2019 | Issued |
Array
(
[id] => 17156120
[patent_doc_number] => 20210317171
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => RECOMBINANT LECTIN VARIANTS
[patent_app_type] => utility
[patent_app_number] => 17/272090
[patent_app_country] => US
[patent_app_date] => 2019-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14608
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 141
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17272090
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/272090 | Recombinant lectin variants | Aug 29, 2019 | Issued |
Array
(
[id] => 17200119
[patent_doc_number] => 20210340214
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN DOSING REGIMENS
[patent_app_type] => utility
[patent_app_number] => 17/271792
[patent_app_country] => US
[patent_app_date] => 2019-08-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16891
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271792
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/271792 | CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN DOSING REGIMENS | Aug 27, 2019 | Abandoned |
Array
(
[id] => 17170354
[patent_doc_number] => 20210324024
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => ENGINEERED SEMAPHORINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/271380
[patent_app_country] => US
[patent_app_date] => 2019-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19036
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271380
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/271380 | ENGINEERED SEMAPHORINS AND USES THEREOF | Aug 26, 2019 | Abandoned |
Array
(
[id] => 16877996
[patent_doc_number] => 11028129
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-06-08
[patent_title] => Compositions for expanding regulatory T cells (Treg) populations, and treating and ameliorating autoimmune diseases and conditions
[patent_app_type] => utility
[patent_app_number] => 16/542168
[patent_app_country] => US
[patent_app_date] => 2019-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 26
[patent_no_of_words] => 20523
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16542168
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/542168 | Compositions for expanding regulatory T cells (Treg) populations, and treating and ameliorating autoimmune diseases and conditions | Aug 14, 2019 | Issued |
Array
(
[id] => 17657068
[patent_doc_number] => 20220177533
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => Recombinant TGF a for wound healing purposes, and the process thereof
[patent_app_type] => utility
[patent_app_number] => 17/266898
[patent_app_country] => US
[patent_app_date] => 2019-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5791
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266898
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/266898 | Recombinant TGF a for wound healing purposes, and the process thereof | Aug 7, 2019 | Pending |
Array
(
[id] => 17990180
[patent_doc_number] => 20220356217
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => Polypeptide Integrin Antagonists
[patent_app_type] => utility
[patent_app_number] => 17/266339
[patent_app_country] => US
[patent_app_date] => 2019-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18901
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266339
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/266339 | Polypeptide integrin antagonists | Aug 7, 2019 | Issued |
Array
(
[id] => 18027826
[patent_doc_number] => 11510987
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-29
[patent_title] => Endocytosis enhancer for drug delivery system
[patent_app_type] => utility
[patent_app_number] => 16/426184
[patent_app_country] => US
[patent_app_date] => 2019-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 49
[patent_no_of_words] => 11657
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16426184
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/426184 | Endocytosis enhancer for drug delivery system | Aug 6, 2019 | Issued |
Array
(
[id] => 15147741
[patent_doc_number] => 20190352348
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-21
[patent_title] => PEPTIDES AND METHODS FOR THE TREATMENT OF DIABETES
[patent_app_type] => utility
[patent_app_number] => 16/531276
[patent_app_country] => US
[patent_app_date] => 2019-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12409
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16531276
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/531276 | Peptides and methods for the treatment of diabetes | Aug 4, 2019 | Issued |
Array
(
[id] => 16060971
[patent_doc_number] => 10689417
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-06-23
[patent_title] => IL-2Rg binding compounds
[patent_app_type] => utility
[patent_app_number] => 16/531989
[patent_app_country] => US
[patent_app_date] => 2019-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 16
[patent_no_of_words] => 111100
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 133
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16531989
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/531989 | IL-2Rg binding compounds | Aug 4, 2019 | Issued |
Array
(
[id] => 16868546
[patent_doc_number] => 20210162013
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => COMPOSITIONS AND METHODS FOR IMPROVING THE BIOAVAILABILITY OF GLP1 AND ANALOGUES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/265747
[patent_app_country] => US
[patent_app_date] => 2019-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14511
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17265747
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/265747 | COMPOSITIONS AND METHODS FOR IMPROVING THE BIOAVAILABILITY OF GLP1 AND ANALOGUES THEREOF | Aug 4, 2019 | Abandoned |